These clinical trials showed that the combination of surgical or medical castration plus the administration of an AR antagonist resulted in only a limited improvement in disease-specific and overall survival in patients with advanced and/or metastasized prostate cancer compared to those who receive castration only [55]. This evidence concerns the gene AR and prostate carcinoma.